BGG announces positive results from MyrtiPro clinical trial

The registered, double-blind, placebo-controlled, randomised parallel-group study involved 32 healthy Japanese adults

BGG World has announced a clinical trial publication related to MyrtiPro for eye health. Building on a previous publication involving a synergistic Bilberry formula, the latest study used 120 mg of MyrtiPro (BGG’s standardised Bilberry extract containing 36% anthocyanins by HPLC).

The registered, double-blind, placebo-controlled, randomised parallel-group study involved 32 healthy Japanese adults who were administered either one MyrtiPro capsule containing 43.2 mg anthocyanins per day or a placebo. The study’s primary outcome was a change in the pupillary response (average of both dominant and non-dominant eyes) between pre- and post-video display terminal (VDT) usage, leading the researchers to conclude the Bilberry extract “inhibited the decrease in accommodative function caused by oxidative stress due to VDT use.” 1

Corresponding researcher Takahiro Sekikawa, PhD, said: “This is a very positive outcome that can lead to daily benefits for millions of computer users, smart phone users and video gamers around the world. It’s extremely encouraging that a relatively low dose of anthocyanins for six weeks was confirmed to safely inhibit the decline in accommodation caused by VDT use and improve eye function.”

BGG’s Global CSO, Yanmei Li, PhD, said: “BGG is proud to continue to invest in clinical research documenting health benefits for our portfolio of ingredients. This is the second study published already in 2021 showing eye health benefits involving MyrtiPro Bilberry.”

Companies